EverCell Bio

Cell Modeling and Karyotyping Services

EverCell Bio and Captivate Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets

By

New collaboration to accelerate the development of pluripotent stem cell derived technologies.

WATERTOWN, Mass., June 14, 2023 /PRNewswire/ — Captivate Bio and EverCell Bio are excited to announce a new collaboration to accelerate the development of pluripotent stem cell derived technologies. Built on the strengths of both companies, this collaboration brings together a shared vision for delivering unique and custom services paired with custom reagents to accelerate research for discovery in regenerative medicine.

This collaboration marks an important development of EverCell Bio’s highly customizable service platform, which includes small to large scale differentiation of neural, hepatic, and cardiac cell types. With a team that has utilized human induced pluripotent stem cells (iPSCs) since they were first derived, EverCell Bio was specifically created to help navigate the challenges of iPSCs and is built to facilitate the application of iPSC technology. Captivate Bio’s experience and approach to contract media manufacturing, reagent sourcing, and customer service, is a natural fit with EverCell Bio’s consultative service offering.

“We are thrilled to partner with Captivate Bio,” said Philip Manos, Founder and President of EverCell Bio. “To fully realize the varied application of iPSCs, access to reliable and customizable regents is a requirement. By partnering with Captivate Bio, not only can we enhance our delivery of customized service offerings, but together, we can help bring further standardization to the field.”

“We are excited for the opportunity to work with the team at EverCell Bio”, said Tanya Potcova, Founder and CEO of Captivate Bio. “We believe the combination of our products and sourcing services with EverCell’s comprehensive range of stem cell services align perfectly with our mission to empower researchers with the tools they need to solve their toughest challenges in the lab.”

Collectively, this collaboration will focus on neural cell modeling, cell expansion, small molecules and proteins, and custom reagent sourcing for drug discovery, clinical translation, and developmental research programs. Both companies will be exhibiting at ISSCR 2023 in Boston from June 14-17, 2023.

About EverCell Bio
EverCell Bio is a highly specialized biotechnology company that provides the most customized and complete pluripotent stem cell (PSC) service solutions to academic, biotechnology and pharmaceutical entities alike. With an advisory team comprised of over 30 years of combined pluripotent stem cell experience, EverCell Bio’s service platform combines operational rigor and flexibility to meet a broad range of scientific needs in an efficient service package.

Located in Natick, Massachusetts, EverCell Bio was founded in 2017 by stem cell scientists in order to deliver a high-class suite of human PSC services that are enhanced by comprehensive experience and dedicated technical support. From reprogramming, gene editing and differentiation, to data generation and validation, EverCell Bio aligns customer needs with the most advanced stem cell technology and techniques in an effective process that yields deliverable results.

Learn more about EverCell Bio at evercellbio.com

About Captivate Bio
Captivate Bio is a scientific solutions provider offering best-in-class customer service, high-quality cell culture products, and media manufacturing services to the stem cell research and therapeutic industries. Our current products include classical media, salt solutions, human platelet lysate, animal sera, cytokines and growth factors, and small molecule kits including the very first CET Cocktail pack for those working with MSCs, hPSCs, NK cells, T cells and more.

Our services include product commercialization and distribution for industry partners, custom reagent sourcing (research and clinical-grade reagents), and custom media manufacturing. Captivate Bio is located in Watertown, Massachusetts.

For more information, visit www.captivatebio.com or follow-on LinkedIn, Facebook, Instagram, and Twitter.

Baker and EverCell Bio Announce Partnership

By

March 2022

The Baker Company, Inc. (“Baker”) a worldwide leader in the manufacture and supply of cell culture, biosafety, and contamination control technologies, has partnered with Evercell Bio, a specialized biotechnology company that facilitates and enhances the application of stem cell-based research by providing the most comprehensive and highest quality of customized cell modeling and product testing services.

The partnership brings continuous, physiologically relevant culture to stem cell workflows using the state-of-the-art SCI-tive Closed Cell Culture workstation.  SCI-tive is a physiological workstation designed to mimic in vivo conditions by providing a continuous cell culture environment with an accurate, homogeneous biological atmosphere including oxygen, CO2, temperature, and humidity levels.

“We look forward to joining forces with Baker to bring a new standard to stem cell services and manufacturing,” said Philip Manos, CEO and founder of EverCell Bio.

Samir Patel, Global Sales Director at the Baker Company, commented, “We are very excited to be able to work closely with the stem cell experts at EverCell Bio.”  He adds, “The EverCell Bio team will carry out some unique experiments to demonstrate the advantages of using a state-of-the-art closed cell workstation featuring physiological oxygen control, when creating and demonstrating stem cell expansion protocols. Therefore, EverCell Bio will become one of the first commercial labs to offer a physiological cell culture component to the range of testing, production and protocol creation services it offers.”

“We are eager to begin to probe the effect more tightly controlled culturing conditions will have on the overall generation and differentiation of stem cells,” said Kara Held, Ph.D., Science Director at the Baker Company.  She continued, “Coupling the techniques developed by EverCell Bio with the state-of-the-art closed cell culture workstation will push the stem cell field to focus on quality and quantity of yield.”

The partnership combines Baker’s expertise with physoxia/hypoxia workstations together with EverCell Bio’s highly customizable stem cell services to create more physiologically and clinically relevant systems. Baker and EverCell Bio are pleased to announce the only SCI-tive demo site in the United States.  Groups are invited to observe the workstation in action or test it out with their own cells.  This will allow biotechnology and pharmaceutical companies as well as academic groups to evaluate the impact of tight oxygen control on their cells and systems of interest.